Vaccination of antibody deficient patients with Prevenar13 - a comparative study between antibody response and cellular immunity. - PNEUMOCE

Karolinska University Hospital, Huddinge, Sweden0 个研究点目标入组 20 人开始时间: 2012年12月11日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. The patients should have been diagnosed with IgG-deficiency; IgG1<2.8 g/l and/or IgG2<1.15 g/L.
•2. The patient should be between 18-65 years of age
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 20

•1. The patient should not have been given Prevenar 7 or 13 prior to the study inclusion.
•2. The patient should not have been given PPV23 2 years prior to the study inclusion.
•3. The patient should not be pregnant.
•4. The patient should not take part in any other clinical study involving drugs or vaccines.
•The healthy controls should be healthy and not be on any drugs that could interfere with an immune response (systemic steroids, NSAIDs, immunosuppressive drugs).

发起方

Karolinska University Hospital, Huddinge, Sweden